Search research articles
Contact Us
Filters
Showing results (81-90 of 103) with videos related to
Page
of 11
Sort By:
Oncogene
|
November 6, 2007
Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma
H Stöcklein, J Smardova, J Macak, et al.
Leukemia
|
August 6, 2015
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
S Ferrero, A Pastore, C W Scholz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 24, 2012
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
M Ghielmini, U Vitolo, E Kimby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2016
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
K Koch, E Hoster, M Ziepert, et al.
Annals of Hematology
|
August 29, 2012
Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting
M Witzens-Harig, G Hess, J Atta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2013
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
M Dreyling, C Thieblemont, A Gallamini, et al.
Leukemia
|
October 16, 2019
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
M Fürstenau, J Bahlo, A M Fink, et al.
Bone Marrow Transplantation
|
February 3, 2015
Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma
A-K Zoellner, S Fritsch, D Prevalsek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2007
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
F Morschhauser, J F Seymour, H C Kluin-Nelemans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2025
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T A Eyre, K Cwynarski, F d'Amore, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 103) with videos related to
Sort By:
Page
of 11
Oncogene
|
November 6, 2007
Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma
H Stöcklein, J Smardova, J Macak, et al.
Leukemia
|
August 6, 2015
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
S Ferrero, A Pastore, C W Scholz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 24, 2012
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
M Ghielmini, U Vitolo, E Kimby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2016
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
K Koch, E Hoster, M Ziepert, et al.
Annals of Hematology
|
August 29, 2012
Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting
M Witzens-Harig, G Hess, J Atta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2013
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
M Dreyling, C Thieblemont, A Gallamini, et al.
Leukemia
|
October 16, 2019
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
M Fürstenau, J Bahlo, A M Fink, et al.
Bone Marrow Transplantation
|
February 3, 2015
Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma
A-K Zoellner, S Fritsch, D Prevalsek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2007
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
F Morschhauser, J F Seymour, H C Kluin-Nelemans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2025
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T A Eyre, K Cwynarski, F d'Amore, et al.
Page
of 11